KUALA LUMPUR, Malaysia—A Singaporean company focused on developing treatments for Alzheimer’s disease has invited banks to pitch for a mandate to advise it on a potential public offering after results come in from late-stage clinical drug trials, expected in the middle of 2016.
The owners of TauRx Pharmaceuticals Ltd., which counts Singapore state investment company Temasek and Southeast Asia’s largest casino operator, Genting, as investors, are looking at listing on the Nasdaq Stock Market as early as 2017 in a deal that could value the company at about $15 billion, according to people familiar with the matter.
A spokesperson for TauRx said the company was holding exploratory discussions with a number of investment banks.
